These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11136718)

  • 1. Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis.
    Johnson CA; Padget K; Austin CA; Turner BM
    J Biol Chem; 2001 Feb; 276(7):4539-42. PubMed ID: 11136718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone Deacetylase Inhibitors Trichostatin A and MCP30 Relieve Benzene-Induced Hematotoxicity via Restoring Topoisomerase IIα.
    Chen J; Zheng Z; Chen Y; Li J; Qian S; Shi Y; Sun L; Han Y; Zhang S; Yu K
    PLoS One; 2016; 11(4):e0153330. PubMed ID: 27058040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines.
    Kurz EU; Wilson SE; Leader KB; Sampey BP; Allan WP; Yalowich JC; Kroll DJ
    Mol Cancer Ther; 2001 Dec; 1(2):121-31. PubMed ID: 12467229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
    Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
    J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase interacts directly with DNA topoisomerase II.
    Tsai SC; Valkov N; Yang WM; Gump J; Sullivan D; Seto E
    Nat Genet; 2000 Nov; 26(3):349-53. PubMed ID: 11062478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibition redistributes topoisomerase IIβ from heterochromatin to euchromatin.
    Cowell IG; Papageorgiou N; Padget K; Watters GP; Austin CA
    Nucleus; 2011; 2(1):61-71. PubMed ID: 21647300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
    Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
    Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cells.
    Aoyama M; Grabowski DR; Isaacs RJ; Krivacic KA; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
    Blood; 1998 Oct; 92(8):2863-70. PubMed ID: 9763571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
    Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
    Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tirapazamine: a hypoxia-activated topoisomerase II poison.
    Peters KB; Brown JM
    Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
    Yamashita M; Tahara T; Hayakawa S; Matsumoto H; Wada SI; Tomioka K; Iida A
    Bioorg Med Chem; 2018 May; 26(8):1920-1928. PubMed ID: 29519604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human topoisomerase IIalpha: targeting to subchromosomal sites of activity during interphase and mitosis.
    Agostinho M; Rino J; Braga J; Ferreira F; Steffensen S; Ferreira J
    Mol Biol Cell; 2004 May; 15(5):2388-400. PubMed ID: 14978217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
    Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
    Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
    Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
    Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression.
    Ashburner BP; Westerheide SD; Baldwin AS
    Mol Cell Biol; 2001 Oct; 21(20):7065-77. PubMed ID: 11564889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide.
    Grabowski DR; Holmes KA; Aoyama M; Ye Y; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
    Mol Pharmacol; 1999 Dec; 56(6):1340-5. PubMed ID: 10570063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-cycle regulation of the DNA topoisomerase IIalpha promoter is mediated by proximal CCAAT boxes: possible involvement of acetylation.
    Adachi N; Nomoto M; Kohno K; Koyama H
    Gene; 2000 Mar; 245(1):49-57. PubMed ID: 10713444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.